(3-氨基吡唑-4-基)(2-噻吩)甲酮 | 96219-87-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: (3-氨基吡唑-4-基)(2-噻吩)甲酮
• 英文名称: (3-amino-1H-pyrazol-4-yl)(thien-2-yl)methanone
• 英文别名: (3-amino-1 H-pyrazol-4-yl)-(2-thienyl)methanone；(3-amino-1H-pyrazol-4-yl)-thiophen-2-yl-methanone；(3-Amino-1H-pyrazol-4-YL)(thiophen-2-YL)methanone；(5-amino-1H-pyrazol-4-yl)-thiophen-2-ylmethanone
• CAS: 96219-87-3
• 化学式: C₈H₇N₃OS
• 分子量: 193.229
• InChiKey: DKSHGSCMEXOBRE-UHFFFAOYSA-N

物化性质

• 熔点：
  144-145 °C
• 沸点：
  515.0±40.0 °C(Predicted)
• 密度：
  1.476±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  100
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  存储条件：2-8°C，避光、干燥密闭保存。

反应信息

• 作为反应物：
  描述：

  (3-氨基吡唑-4-基)(2-噻吩)甲酮 在 铁粉 、 氯化铵 、 溶剂黄146 作用下， 以 甲醇 为溶剂， 生成 [7-(3-aminophenyl)pyrazolo[1,5-a]pyrimidin-3-yl]-thien-2-yl-methanone
  参考文献：
  名称：

  Pyrazolo[1,5-a]pyrimidin-7-yl phenyl amides as novel anti-proliferative agents: parallel synthesis for lead optimization of amide region

  摘要：

  A novel series of p21 chemoselective agents containing a pyrazolo[1,5-a]pyrimidin-7-yl phenyl amides were identified by high throughput screening. Optimization of the amide region by parallel synthesis and the iterative design toward understanding structure-activity relationship to improve potency are described. The isopropyl carbamate derivative 34 was identified as a highly chemoselective agent displaying a potency of 51 nM in the p21 deficient cell line. © 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.01.066
• 作为产物：
  描述：

  2-乙酰基噻吩 在 一水合肼 作用下， 反应 36.0h， 生成 (3-氨基吡唑-4-基)(2-噻吩)甲酮
  参考文献：
  名称：

  Pyrazolo[1,5-a]pyrimidin-7-yl phenyl amides as novel antiproliferative agents: Exploration of core and headpiece structure–activity relationships

  摘要：

  A novel series of antiproliferative agents containing pyrazolo[1,5-a]pyrimidin-7-yl phenyl amides, selective for p21-deficient cells, were identified by high-throughput screening. Exploration of the SAR relationships in the headpiece, core, and tailpiece is described. Strict steric, positional, and electronic requirements were observed, with a clear preference for both core nitrogens, a thienoyl headpiece, and meta substituted tailpiece. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.12.116
• 作为试剂：
  描述：

  (3-氨基吡唑-4-基)(2-噻吩)甲酮 、 N-[5-[(E)-3-(dimethylamino)prop-2-enoyl]-2-fluorophenyl]-N-methylacetamide 在 (3-氨基吡唑-4-基)(2-噻吩)甲酮 作用下， 以75的产率得到Lorediplon标准品
  参考文献：
  名称：

  Process for the manufacture of a crystalline pyrazolo[1,5-a]pyrimidine compound

  摘要：

  本发明涉及一种工业制造 N-{2-氟-5-[3-(噻吩-2-羰基)-吡唑并[1,5-a]嘧啶-7-基]-苯基}-N-甲基乙酰胺 B 晶型的新工艺。

  公开号：

  US08008486B2

文献信息

• Salts And Co-Crystals of Pyrazolopyrimidine Compounds, Compositions Thereof And Methods For Their Production And Use
  申请人：LIPPA S. Arnold

  公开号：US20080045547A1

  公开（公告）日：2008-02-21

  The invention provides pharmaceutically acceptable salts and co-crystals of pyrazolopyrimidine compounds such as zaleplon, indiplon and ocinaplon, processes for their preparation, compositions comprising such salts and co-crystals and methods of using such salts and co-crystals for treating various diseases and conditions.

  这项发明提供了吡唑基嘧啶化合物的药用可接受盐和共晶体，例如扎来普隆、印地普隆和奥西那普隆，以及它们的制备方法、包含这些盐和共晶体的组合物，以及利用这些盐和共晶体治疗各种疾病和症状的方法。
• Synthesis, SAR study and biological evaluation of novel pyrazolo[1,5-a]pyrimidin-7-yl phenyl amides as anti-proliferative agents
  作者：Yanong D. Wang、Erick Honores、Biqi Wu、Steve Johnson、Dennis Powell、Miriam Miranda、John P. McGinnis、Carolyn Discafani、Sridhar K. Rabindran、Wendy Cheng、Girija Krishnamurthy

  DOI：10.1016/j.bmc.2008.12.046

  日期：2009.3

  upstream activator, p53, and is associated with poor prognosis in some cancer patients. Using an isogenic pair of cell lines, HCT116 (p21+/+) and 80S14 (p21−/−), we have disclosed previously a novel series of pyrazolo[1,5-a]pyrimidines that preferentially kill the p21-deficient cells. We will present the synthesis, biological activities and SAR study of a series of pyrazolo[1,5-a]pyrimidines with an

  恶性细胞检查点不足可用于开发癌症药物。可以选择性地杀死缺乏检查点的细胞和具有检查点的细胞的化合物来优先靶向肿瘤细胞，同时保留正常细胞。蛋白质p21 Wafl / Cipl / Sdi1（下文称为p21）通过抑制G1激酶（cyclin D / cdk4和cyclin E-cdk2）和G2激酶（cyclin B / cdkl）的活性来抑制细胞周期的进展，以响应DNA损伤或异常DNA含量。由于上游激活因子p53的频繁丢失，人癌细胞中p21的表达通常较低，并且与某些癌症患者的预后不良有关。使用同等基因对的细胞系HCT116（p21 + / +）和80S14（p21-/-），我们先前已经公开了一系列新颖的吡唑并[1,5- a ]嘧啶，可优先杀死p21缺陷型细胞。我们将介绍一系列吡唑并[1,5- a在C-7位置具有优化的苯基酰胺部分的]嘧啶。这些化合物的作用机理也将被讨论。
• Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-&agr;]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
  申请人：Neurocrine Biosciences, Inc.

  公开号：US06384221B1

  公开（公告）日：2002-05-07

  Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-&agr;]-pyrimidin-7-yl}phenyl)acetamide (Compound 1), and use of the same as a sedative-hypnotic, anxiolytic, anticonvulsant, and skeletal muscle relaxant agent. Processes for making the same, as well as related compositions and methods are also disclosed, particularly with regard to treatment of insomnia. A polymorph Form I possessing exception physical and heat stability is provided. A polymorph Form II

  N-甲基-N-(3-3-[2-噻吩甲酰]-吡唑-[1,5-α]-嘧啶-7-基}苯基)乙酰胺（化合物1）的多态形式，以及将其用作镇静催眠剂、抗焦虑剂、抗抽搐剂和骨骼肌松弛剂的用途。还公开了制备该化合物的方法，以及相关的组合物和方法，特别是关于治疗失眠的方法。提供了具有特殊物理和热稳定性的多态形式I。多态形式II。
• [EN] N-[3-(3-SUBSTITUTED-PYRAZOLO[1,5-a]PYRIMIDIN-7-YL)PHENYL]-SULFONAMIDES, AND COMPOSITIONS, AND METHODS RELATED THERETO<br/>[FR] N-[3-(3-SUBSTITUÉS-PYRAZOLO[1,5-A]PYRIMIDIN-7-YL)PHÉNYL]-SULFONAMIDES ET COMPOSITIONS ET MÉTHODES ASSOCIÉES
  申请人：FERRER INT

  公开号：WO2005014597A1

  公开（公告）日：2005-02-17

  The present invention relates to compounds of Formula (I): wherein R1, R2 and R3 are as defined in the claims. The compounds have specific affinity for the GABAA receptor and are therefore useful in the treatment and prevention of diseases modulated by the α1- and α2-GABAA receptors.

  本发明涉及式（I）的化合物：其中R1、R2和R3如权利要求中所定义。这些化合物具有特定的亲和力，适用于治疗和预防受α1-和α2-GABAA受体调节的疾病。
• Method of using substituted pyrazolo [1,5-a] pyrimidines
  申请人：Wang Daniel Yanong

  公开号：US20060063784A1

  公开（公告）日：2006-03-23

  This invention relates to novel methods of use of certain pyrazolo[1,5-a]pyrimidine compounds and the therapeutically acceptable salts thereof. This invention also relates to novel methods of using these compounds as anti-proliferative agents in mammals, including humans.

  这项发明涉及某些吡唑并[1,5-a]嘧啶化合物及其治疗上可接受的盐的新用途方法。该发明还涉及将这些化合物作为抗增殖剂在哺乳动物，包括人类中的新用途方法。